Travere Therapeutics, Inc.
NASDAQTravere Therapeutics enters the week of October 29 earnings with an uncomfortable gap between where analysts think the stock should trade and where it actually is — and short sellers showing no sign of walking away. The stock closed at $60.28 on Tuesday, down 4.1% on the day and off 8.3% over the past month. That slide has pushed it meaningfully below a Street consensus target of…
Snapshot as of 17 Oct 2026
Travere Therapeutics enters the week of October 29 earnings with an uncomfortable gap between where analysts think the stock should trade and where it actually is — and short sellers showing no sign of walking…
Travere Therapeutics delivered its Q2 earnings on August 4 and the Street's response was immediate — multiple firms lifted targets on the same morning, validating the bullish setup that had been building for weeks. The…
TVTX heads into its August 6 earnings print with short sellers retreating and analysts raising targets — a rare alignment of two signals pointing in the same direction. Short interest has declined meaningfully over the…
Travere Therapeutics heads into early June with a familiar tension: analysts raising targets and the Street broadly bullish on FILSPARI's rare-disease story, while a 15.6% short interest and a cluster of insider…
Travere Therapeutics arrives at the close of this week carrying two competing stories: a Q1 earnings beat that pulled the entire sell-side to raise its targets, and a cluster of insider sales from the same management…
Travere Therapeutics heads into its May 7 earnings with a striking divergence: short sellers have been exiting while analysts race to raise targets, leaving the stock 47% higher than a month ago with defensive options…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for TVTX — free to start on ORTEX.
Sign up for free →Open TVTX on ORTEX